Our CEO Alice Zhang is honored to be a keynote speaker at the?Longevity Platinum Trip, where she will be sharing insights on how Verge is contributing enhancing health-spans through CONVERGE??our AI-driven drug discovery and development platform.?#AI #Biotech #VergeGenomics #DrugDiscovery #Innovation #Healthspan?
Verge Genomics
生物技术研究
South San Francisco，California 15,292 位关注者
Better drugs, faster. For patients who can’t wait.
关于我们
Verge Genomics is a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data. Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning. Verge has created a proprietary all-in-human CONVERGE? platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The company is led by experienced computational biologists and drug developers who are successfully advancing clinical and preclinical therapeutic programs in various diseases, including ALS and Parkinson’s disease. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
- 网站
-
https://www.vergegenomics.com
Verge Genomics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Bioinformatics、Genomics、Drug Discovery、Neuroscience、ALS和FTD
地点
-
主要
获取路线
131 Oyster Point Blvd
US，California，South San Francisco，94080
Verge Genomics员工
动态
-
Don’t miss Verge CMO, Diego Cadavid's presentation on our PIKfyve inhibitor VRG50635 at #ANA2024 next week! VRG50635, a potential treatment for #ALS, is a major milestone being one of the first drugs discovered and developed from an #AI-powered platform to go to clinic. Don’t miss the opportunity to learn more! ? We look forward to connecting and discussing the future of #drugdiscovery. #ANA2024 #ArtificialIntelligence
-
-
Verge Genomics was thrilled to be honored with the 2023 Pantheon Award for Emerging Innovation. At Verge, we are leveraging AI to unlock new drugs for some of the biggest medical challenges of our time. Help us celebrate the next wave of innovators!?As we pass the torch, we urge you to nominate visionary companies breaking new ground in life sciences innovation.?Learn more about nominations on the Awards Methodologies & Disclosures page:?https://lnkd.in/eAjR6KXx?and submit your nominations here:?https://bit.ly/3YaDBom #PantheonAwards #EmergingInnovation #LifeSciences #AI
-
-
Join Verge Genomics Diego Cadavid next week at the European Network to Cure ALS (ENCALS) in Stockholm! ? This is a great opportunity to get an update on Verge's unique proof-of-concept study on VRG50635, a small-molecule PIKfyve inhibitor being investigated as a potential treatment for all forms of ALS. #ALS #ENCALS24 #ALSResearch?#AIDrugDiscovery
-
-
We are thrilled to share an insightful article by our CEO, Alice Zhang, featured in Fortune. Alice's thoughtful perspective on leading with empathy, embracing vulnerability, and fostering a culture of transparency and trust, highlights how these principles are integral to Verge's mission and hopefully will inspire leaders across all industries. Check out the full article here:?The Importance of Conscious Leadership https://lnkd.in/e5WtY966
What companies are going to prevail in this post-AI world? Those that build the right cultures. In inventive work, the best teams outperform the average ones by 10X. There is a huge premium on building creative, effective teams of the best caliber in AI. Today, I write in Fortune about how re-defining corporate culture is the most overlooked aspect of building a successful AI-enabled company. Today's leaders don't pound their fists on the table and talk about how they're crushing it. They have the courage to simply be vulnerable.
-
Meet the Verge Genomics BD Team, Michelle Mighdoll & Sam Galindo, at #BIO2024! Looking forward to connect and collaborate June 3-6, 2024. #BIO2024?#AI
-
-
Be sure to catch Verge Genomics Irene Choi at this week’s #DiscoveryEurope24 where she will share insights on how Verge's AI platform CONVERGE? is used to?to identify novel targets, an overview of our proof-of-concept study for a potential ALS therapy that was?discovered and developed using Verge’s AI platform and the future of AI/ML in drug discovery and beyond!?Details are below. #DiscoveryEurope24 #VergeGenomics #AI #DrugDiscovery?#OGDiscovery?
-
-
We are thrilled that Verge Genomics' CMO Diego Cadavid is presenting at the 3rd Annual ALS Drug Development Summit on May 23rd at 11:30 AM.?Diego will?share insights on Verge’s groundbreaking proof-of-concept study design to evaluate VRG50635 as a potential novel therapeutic candidate for ALS. Don't miss this opportunity to learn more about VRG50635 and the future of ALS treatment!? https://ter.li/qdfuop Location: Hyatt Regency Boston, 1 Ave de Lafayette, Boston, MA 02111 #ALS #ALSresearch #ALSdrugdevelopment
-
-
We're pleased to partner with?Ferrer to co-develop VRG50635, our lead drug candidate for the treatment of sporadic and familial forms of #ALS. Hear our President and Chief Business Officer, Jane Rhodes, share how our #innovation and Ferrer's experience create a complementary partnership as we progress a potential treatment for this devastating disease. #biotechnology #drugdevelopment?
We are delighted to announce an important news for people living with amyotrophic lateral sclerosis (ALS), their families, and their caregivers, thanks to our a strategic collaboration with Verge Genomics to co-develop one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. ? According to Mario Rovirosa, our CEO, "in line with our purpose to use business to fight for social justice, we are reinforcing our commitment to bring transformative therapeutic solutions for people living with severe and debilitating diseases”. ? We are Ferrer. Ferrer for good ???? More info: https://lnkd.in/diWtUBMx
-
Exciting News! Verge Genomics and Ferrer are collaborating to advance VRG50635, Verge’s lead drug candidate for treating both sporadic and familial forms of #ALS. This partnership, Verge’s third with a major pharma company, underscores the value of the CONVERGE? platform in identifying novel targets for complex diseases. VRG50635 is one of the first candidate drugs to enter the clinic that was entirely discovered and developed using #AI. By combining Verge's all-in-human technology with Ferrer's global expertise in clinical development and commercialization, we aim to make a meaningful impact on those affected by ALS. For more information, read the announcement: https://bit.ly/3PA1ctA #Innovation #AIinhealthcare #DrugDevelopment
-